title: Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Management of Peritoneal Sarcomatosis: A Preliminary Single-Center Experience from Saudi Arabia.
abstract: Aim. To report our preliminary single-center experience with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for management of peritoneal sarcomatosis (PS). Methods. Eleven patients were retrospectively analyzed for perioperative details. Results. Cytoreduction completeness (CC-0/1) was achieved in all patients with median peritoneal cancer index (PCI) of 14 ± 8.9 (range: 3-29). Combination cisplatin + doxorubicin HIPEC chemotherapy was used in 6 patients. Five patients received intraoperative radiation therapy (IORT). The median operative time, estimated blood loss, and hospital stay were 8 ± 1.4 hours (range: 6-10), 1000 ± 250 mL (range: 700-3850), and 11 ± 2.4 days (range: 7-15), respectively. Major postoperative Clavien-Dindo grade III/IV complications occurred in 1 patient and none developed HIPEC chemotherapy-related toxicities. The median overall survival (OS) and disease-free survival (DFS) after CRS + HIPEC were 28.3 ± 3.2 and 18.0 ± 4.0 months, respectively. The median follow-up time was 12 months (range: 6-33). Univariate analysis of several prognostic factors (age, gender, PS presentation/pathology, CC, PCI, HIPEC chemotherapy, and IORT) did not demonstrate statistically significant differences of OS and DFS. Conclusion. CRS + HIPEC appear to be feasible, safe, and offer survival oncological benefits. However, definitive conclusions cannot be deduced.
authors.affiliation: College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Abu-Zaid
authors.affiliation: Faculty of Medicine, Alexandria University, Alexandria 21526, Egypt; King Faisal Oncology Centre, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia.
authors.forename: Ayman
authors.initials: A
authors.lastname: Azzam
authors.affiliation: Department of Obstetrics and Gynecology, King Fahad Medical City, Riyadh 11525, Saudi Arabia.
authors.forename: Mohammed
authors.initials: M
authors.lastname: Abuzaid
authors.affiliation: King Faisal Oncology Centre, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia.
authors.forename: Tusneem
authors.initials: T
authors.lastname: Elhassan
authors.affiliation: College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
authors.forename: Naryman
authors.initials: N
authors.lastname: Albadawi
authors.affiliation: College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
authors.forename: Lynn
authors.initials: L
authors.lastname: Alkhatib
authors.affiliation: Department of Obstetrics and Gynecology, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia.
authors.forename: Osama
authors.initials: O
authors.lastname: AlOmar
authors.affiliation: King Faisal Oncology Centre, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia.
authors.forename: Abdullah
authors.initials: A
authors.lastname: Alsuhaibani
authors.affiliation: King Faisal Oncology Centre, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia.
authors.forename: Tarek
authors.initials: T
authors.lastname: Amin
authors.affiliation: College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia; Department of Obstetrics and Gynecology, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia.
authors.forename: Ismail A
authors.initials: IA
authors.lastname: Al-Badawi